<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00549536</url>
  </required_header>
  <id_info>
    <org_study_id>A3242</org_study_id>
    <nct_id>NCT00549536</nct_id>
  </id_info>
  <brief_title>The Effect of Calcium Supplementation on Insulin Resistance and 24h Blood Pressure</brief_title>
  <official_title>The Effect of Oral Calcium Supplementation on Insulin Sensitivity, Intracellular Cationic Concentrations and the Transmembrane Sodium/Hydrogen Exchanger Activity in Subjects With Type 2 Diabetes and Hypertension</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Aristotle University Of Thessaloniki</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Hellenic Society of Hypertension</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Aristotle University Of Thessaloniki</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Increased levels of intracellular calcium are thought to diminish maximal cellular response
      to insulin and induce insulin resistance. Also, both hypertension and diabetes are thought to
      be conditions of altered intracellular ionic state. The aim of the present study is to
      investigate the possible effect of oral calcium supplementation on intracellular ions,
      insulin sensitivity, 24-h blood pressure and sodium/hydrogen exchanger activity in patients
      with type 2 diabetes and essential hypertension.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2007</start_date>
  <completion_date type="Actual">May 2008</completion_date>
  <primary_completion_date type="Actual">May 2008</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To evaluate the difference in 24h blood pressure measurement and insulin sensitivity between the treatment and the control group.</measure>
    <time_frame>baseline and after 8 weeks of follow up</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>To evaluate differences in intracellular calcium, magnesium, sodium and potassium concentrations at the end of the follow up period between the calcium supplementation group and the control group.</measure>
    <time_frame>baseline and after 8 weeks of follow up</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To evaluate differences in the transmembrane sodium/hydrogen exchanger activity between the active treatment and the control group.</measure>
    <time_frame>baseline and after 8 weeks of follow up</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">31</enrollment>
  <condition>Hypertension</condition>
  <condition>Diabetes</condition>
  <condition>Insulin Resistance</condition>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients on calcium supplementation</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>tablets each containing of 1000mg elemental calcium (Mega-Calcium Sandoz)</intervention_name>
    <description>1500 mg of elemental calcium per day.</description>
    <arm_group_label>2</arm_group_label>
    <arm_group_label>1</arm_group_label>
    <other_name>Mega-Calcium Sandoz</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with hypertension, diabetes and the metabolic syndrome (according to the
             definition of the National Cholesterol Education Program, Adult Panel III (NCEP, ATP
             III).

          -  Signed the concent form

        Exclusion Criteria:

          -  Secondary Hypertension

          -  Stage II or III hypertension

          -  History of renal disease

          -  Sleep apnea

          -  Acute or chronic inflammation

          -  History of coronary artery disease

          -  Heart failure stage III or IV according to the New York Heart Association

          -  Active liver disease

          -  History of malignancy

          -  Parathyroidism

          -  History of kidney stones

          -  Calcium supplement ingestion

          -  Drugs that alter insulin resistance

          -  Treatment with insulin

          -  Alcohol abuse or other conditions with poor prognosis

          -  Treatment with non-inflammatory steroid agents, corticosteroids, or any other
             treatment that affects blood pressure
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Anastasios N. Lasaridis, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>1st Department of Internal Medicine, AHEPA University Hospital, Aristotle University of Thessaloniki, Greece</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Maria I. Pikilidou, MD, MSc</last_name>
    <role>Study Director</role>
    <affiliation>1st Department of Internal Medicine, AHEPA University Hospital, Aristotle University of Thessaloniki, Greece</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>AHEPA University Hospital</name>
      <address>
        <city>Thessaloniki</city>
        <zip>54636</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Greece</country>
  </location_countries>
  <verification_date>June 2008</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 25, 2007</study_first_submitted>
  <study_first_submitted_qc>October 25, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 26, 2007</study_first_posted>
  <last_update_submitted>July 2, 2008</last_update_submitted>
  <last_update_submitted_qc>July 2, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 4, 2008</last_update_posted>
  <responsible_party>
    <name_title>Lasaridis Anastasios</name_title>
    <organization>1st Department of medicine AHEPA University Hospital</organization>
  </responsible_party>
  <keyword>calcium supplementation</keyword>
  <keyword>intracellular ions</keyword>
  <keyword>sodium/hydrogen exchange activity</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
    <mesh_term>Insulin Resistance</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Calcium, Dietary</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

